Clearmind Medicine Inc. - Common Shares (NQ:CMND)

6.715 +0.115 (+1.75%)

Delayed Quote Updated: 11:30 AM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes ↗

August 23, 2024

Clearmind Medicine secures a U.S. patent for its MEAI-based binge behavior treatment, marking a significant advancement in addressing Alcohol Use Disorder.

Via Benzinga

Topics Intellectual Property

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment

August 21, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

August 16, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

August 09, 2024

We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns!

Via InvestorPlace

CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024 ↗

June 17, 2024

Clearmind Medicine just reported results for the second quarter of 2024.

Via InvestorPlace

Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket ↗

August 09, 2024

Via Benzinga

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug

August 06, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

August 06, 2024

From SciSparc Ltd

Via GlobeNewswire

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research

July 31, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product

July 19, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Nasdaq Edges Lower; Morgan Stanley Earnings Top Views ↗

July 16, 2024

Via Benzinga

Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 16, 2024

Via Benzinga

Crude Oil Down 1%; Bank of America Posts Upbeat Earnings ↗

July 16, 2024

Via Benzinga

Why Is SciSparc (SPRC) Stock Up 25% Today? ↗

July 16, 2024

SciSparc stock is up on Tuesday as SPRC investors learn of the company filing a new patent covering its weight loss treatment.

Via InvestorPlace

Topics Intellectual Property

Dow Jumps 400 Points; US Retail Sales Flat For June ↗

July 16, 2024

Via Benzinga

Topics Stocks

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism

July 16, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

July 16, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

July 16, 2024

From SciSparc Ltd

Via GlobeNewswire

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

July 12, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher ↗

June 28, 2024

Clearmind Medicine shares are trading higher Friday after the company announced advancement in its proprietary MEAI-based binge behavior regulator program through the granting of patent approval in...

Via Benzinga

Topics Intellectual Property

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

June 28, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Day Trading My Way From Red To Green ↗

June 23, 2024

I set daily profit goals and max loss limits to manage my risk. My daily goal is $5,000, and I cap my daily loss at the same amount.

Via Talk Markets

Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment

June 20, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

What's Going On With Clearmind Medicine Stock Tuesday? ↗

June 11, 2024

Clearmind said its alcohol substitute was granted patents in the U.S., India and Europe. The company also highlighted that the no/low alcohol category is forecasted to grow at a volume CAGR of more...

Via Benzinga

Topics Intellectual Property

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

June 11, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

May 10, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Why Clearmind Medicine Stock Is Moving Higher ↗

May 07, 2024

Clearmind Medicine shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development.

Via Benzinga

Topics Intellectual Property

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

May 07, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 07, 2024

Via Benzinga

Clearmind Applies to Cease Being a Reporting Issuer in Canada

April 30, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.